Found this on valuetech... seems like the 0.007-0.006 (cap 4-5mil) seems like a good base. The question is where thus it go from there? I've in fermiscan since... well it's been to long and costly to remember; but I've always been a big believer in the technology. I also like to think that the focus of our previous board was intoxicated by there enthusiasm over the test. Also, the fact that they had loads of cash at the start-up of fermiscan fuelled there overconfidence. Anyway I care to believe in the new management... why? Because they are putting effort in an 'empty' box with very limited cash,...clearly the box must not be that empty as it seems and why go trough the trouble of finish the trails if there isn't a 'NEXT STEP' strategy.
I bought some @ .7c because this one is currently cheaper and has more chance than a lottery ticket ;-)
Regards D.Jazz --------BEAR with me BULL---------
FER - Fermiscan Holdings Ltd. Company investigating the detection of breast cancer through an apparent change in the structure of hair samples. Even if the test works (other research groups have not been able to confirm the findings apparently due to different sample preparation protocols), there will be questions about specificity, timeliness and cost which could affect the degree of commercialisation. As a result, the current market cap of the company is reasonable at $4 million with speculation driving prices (up 50% in 2006 following listing at end of October 2006, down 2% in 2007, down 80% in 2008 and down 85% in 2009). In April 2009, merger proposal between Polartechnics and Fermiscan announced with a significant fall in price and this proposal was not concluded when the expert's report found that the proposal was neither fair nor reasonable. There was a limited recovery in value with commencement of precommercial trials in Australia and turnover on the Board. However, significant losses have led to review of strategy by new Board, sale of Breast Cancer Clinic at significant loss and potential for sale of Fermiscan technology. The litigation against the inventor of the technology failed and failed again on appeal with significant costs to the company which was then forced into voluntary administration. The administrator has sold the IP of the company for a negligible amount, has wound up subsidiaries and the company shell remains. Administrator is no longer in place and company is under advice of two accounting companies which are restructuring the Board, putting in place funding for clinical trials and seeking reinstatement to the ASX. An agreement has been reached for conclusion of clinical trials but a question remains about relevance of trial conclusion if company no longer possesses the relevant intellectual property. Reinstatement to official quotation occurred in March 2011 with fall of 73% to $5 million. (5/4/11)
FER Price at posting:
0.6¢ Sentiment: LT Buy Disclosure: Held
